StockNews.com Initiates Coverage on Navidea Biopharmaceuticals (NYSE:NAVB)
Equities research analysts at StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a note issued to investors on Wednesday. The firm set a “sell” rating on the stock. Navidea Biopharmaceuticals Price Performance NAVB opened at $0.00 on Wednesday. The company has a market capitalization of $100,084.00, a P/E ratio […]
More Stories
The Color Revolution Comes Home: Ex-USAID Operatives, DSA Networks, and a Playbook Aimed at the American Republic
By Stephen Zogopoulos, USNN World News In the interview titled “DataRepublican: The Democrat Plan For A Color Revolution: Everything You...
Trump Admin Can Detain Illegal Immigrants Without Bond Hearings: Appeals Court
By Zachary Stieber President Donald Trump’s administration can hold illegal immigrants in detention without bond hearings, a full federal appeals...
Florida Mayor Arrested After Authorities Say She Paid Herself and Family State COVID Funds
By Jill McLaughlin State authorities arrested the mayor of the central Florida city of Kissimmee on Oct. 21, charging her...
American Express Laying Off 5 Percent of Workforce
By Andrew Moran American Express said it is laying off about 5 percent of its workforce. The global payment services...
Typhoon Champi Leaves 1 Dead, 350 Injured in Taiwan; Alters US-Japan Military Exercise
By Arthur Zhang Typhoon Champi left one person dead and 350 injured in Taiwan, disrupting air and rail travel and...
Russian Diesel Expected to Arrive on Nov. 7 After Trump-Putin Deal
By Tom Ozimek A tanker carrying 40,000 metric tons of Russian diesel is heading toward New York following a deal...